Димитриос Каруссис

Отделение: Неврология
Должность: Невролог, специалист в области лечения рассеянного склероза
Принимает: только взрослых


Профессор Димитриос Каруссис - директор центра нейроиммунологии и лечения рассеянного склероза



Профессор неврологии Еврейского Университета с 2003 г.

Образование

Профессор Карусис родился 7-го августа 1962-го года в городе Салоники, Греция.
Выпускник медицинской школы “Аристотелион” в Салониках (1986 г.)
Завершил ординатуру при отделении неврологии университетской клиники “Хадасса” в Иерусалиме (1989-1994 гг.)
В 1994 г. защитил диссертацию на степень доктора наук (PhD) в области нейробиологии.
С 1998 г. руководитель центра лечения рассеянного склероза при отделении неврологии.

Научные публикации

The preclinical data and immunologic rationale for hematopoietic stem cell transplantation in autoimmunity
Granagard administration prolongs the survival of human mesenchymal stem cells transplanted into a mouse model of multiple sclerosis
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies
Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group‏ Viewpoint
Application of diagnostic criteria for optic neuritis - Authors' reply
Diagnosis and classification of optic neuritis
A case report of unilateral cervical lymphadenopathy and multiple cranial neuropathies following mRNA-COVID-19 vaccination
Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: YES
Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers in Progressive Multiple Sclerosis
Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses
Anatomical and functional visual network patterns in progressive multiple sclerosis
A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis
Beneficial effects of a nano formulation of pomegranate seed oil, GranaGard, on the cognitive function of multiple sclerosis patients
Long-Term Clinical and Immunological Effects of Repeated Mesenchymal Stem Cell Injections in Patients With Progressive Forms of Multiple Sclerosis
Synergistic neuroprotective effects of Fingolimod and mesenchymal stem cells (MSC) in experimental autoimmune encephalomyelitis
Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis
Conduction delays in the visual pathways of progressive multiple sclerosis patients covary with brain structure
Cerebrospinal Fluid (CSF) Exchange Therapy with Artificial CSF Enriched with Mesenchymal Stem Cell Secretions Ameliorates Cognitive Deficits and Brain Pathology in Alzheimer's Disease Mice
Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT
MULTIPLE SCLEROSIS THERAPY - 2019
Neuralized mesenchymal stem cells (NMSC) exhibit phenotypical, and biological evidence of neuronal transdifferentiation and suppress EAE more effectively than unmodified MSC
Vision and Vision-Related Measures in Progressive Multiple Sclerosis
The Second Greek-Israeli Symposium on Autoimmunity and Rheumatology: Success Through Synergy
Cerebrospinal Fluid (CSF) Exchange with Artificial CSF Enriched with Mesenchymal Stem Cell Secretions Ameliorates Experimental Autoimmune Encephalomyelitis
Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale
NMO-IgG and AQP4 Peptide Can Induce Aggravation of EAMG and Immune-Mediated Muscle Weakness
Development of a Novel Backbone Cyclic Peptide Inhibitor of the Innate Immune TLR/IL1R Signaling Protein MyD88
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Cell-based therapeutic strategies for multiple sclerosis
Sodium intake and multiple sclerosis activity and progression in BENEFIT
Low-Density Lipoprotein Receptor-Related Protein 4-Positive Myasthenia Gravis in a Double-Seronegative, Electromyography-Negative Patient
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
The 11-year long-term follow-up study from the randomized BENEFIT CIS trial
T-cell responses to distinct AQP4 peptides in patients with neuromyelitis optica (NMO)
Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel
Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials
Sex-specific prediction of interferon beta therapy response in relapsing-remitting multiple sclerosis
Tumefactive demyelination following in vitro fertilization (IVF)
Delayed-onset flaccid paralysis related to west Nile virus reactivation following treatment with rituximab: a case report
Increased anti-KIR4.1 antibodies in multiple sclerosis: could it be a marker of disease relapse?
NMO spectrum of disorders: a paradigm for astrocyte-targeting autoimmunity and its implications for MS and other CNS inflammatory diseases
The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review
The spectrum of post-vaccination inflammatory CNS demyelinating syndromes
Rare combination of myasthenia and motor neuronopathy, responsive to Msc-Ntf stem cell therapy
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage
Mesenchymal stem cells (MSC) derived from mice with experimental autoimmune encephalomyelitis (EAE) suppress EAE and have similar biological properties with MSC from healthy donors
Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation
Characterization of human sporadic ALS biomarkers in the familial ALS transgenic mSOD1(G93A) mouse model
Hematopoietic stem cell transplantation in multiple sclerosis
Показать ещё 42 статьи Скрыть статьи
Заболевания
Рассеянный склероз
Оптический нейромиелит
Миастения гравис
Аутоиммунные нейропатии
Процедуры
Трансплантация мезенхимальных стволовых клеток в лечении рассеянного склероза
Остались вопросы?
Напишите нам и мы свяжемся с вами в течение ближайшего времени и ответим на все интересующие вопросы